(Q)SAR Modeling and Safety Assessment in Regulatory Review

The ability to predict clinical safety based on chemical structures is becoming an increasingly important part of regulatory decision making. (Quantitative) structure–activity relationship ((Q)SAR) models are currently used to evaluate late‐arising safety concerns and possible nonclinical effects of a drug and its related compounds when adequate safety data are absent or equivocal. Regulatory use will likely increase with the standardization of analytical approaches, more complete and reliable data collection methods, and a better understanding of toxicity mechanisms.

[1]  Naomi L Kruhlak,et al.  Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models. , 2007, Regulatory toxicology and pharmacology : RTP.

[2]  J. Contrera,et al.  A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software. , 1998, Regulatory toxicology and pharmacology : RTP.

[3]  E. Matthews,et al.  Prediction of drug-related cardiac adverse effects in humans--A: creation of a database of effects and identification of factors affecting their occurrence. , 2010, Regulatory toxicology and pharmacology : RTP.

[4]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[5]  E. Matthews,et al.  Prediction of drug-related cardiac adverse effects in humans--B: use of QSAR programs for early detection of drug-induced cardiac toxicities. , 2010, Regulatory toxicology and pharmacology : RTP.

[6]  Naomi L Kruhlak,et al.  Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. , 2007, Advanced drug delivery reviews.

[7]  Naomi L Kruhlak,et al.  Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities. , 2009, Regulatory toxicology and pharmacology : RTP.

[8]  Naomi L Kruhlak,et al.  Development of a Phospholipidosis Database and Predictive Quantitative Structure-Activity Relationship (QSAR) Models , 2008, Toxicology mechanisms and methods.

[9]  Naomi L Kruhlak,et al.  Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities. , 2009, Regulatory toxicology and pharmacology : RTP.

[10]  N. Kruhlak,et al.  In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software. , 2005, Regulatory toxicology and pharmacology : RTP.

[11]  R Daniel Benz,et al.  Toxicological and clinical computational analysis and the US FDA/CDER , 2007, Expert opinion on drug metabolism & toxicology.

[12]  N. Kruhlak,et al.  An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpoints. , 2006, Regulatory toxicology and pharmacology : RTP.

[13]  N. Kruhlak,et al.  Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. , 2004, Regulatory toxicology and pharmacology : RTP.

[14]  N. Kruhlak,et al.  Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data. , 2004, Current drug discovery technologies.

[15]  Naomi L Kruhlak,et al.  A comprehensive model for reproductive and developmental toxicity hazard identification: II. Construction of QSAR models to predict activities of untested chemicals. , 2007, Regulatory toxicology and pharmacology : RTP.

[16]  Wolfgang Muster,et al.  Computational toxicology in drug development. , 2008, Drug discovery today.

[17]  Mark T D Cronin,et al.  The Current Status and Future Applicability of Quantitative Structure–activity Relationships (QSARs) in Predicting Toxicity , 2002, Alternatives to laboratory animals : ATLA.

[18]  R. Saracci,et al.  Describing the validity of carcinogen screening tests. , 1979, British Journal of Cancer.

[19]  W. Tong,et al.  Quantitative structure‐activity relationship methods: Perspectives on drug discovery and toxicology , 2003, Environmental toxicology and chemistry.

[20]  Wolfgang Muster,et al.  Strategies for Using Computational Toxicology Methods in Pharmaceutical R&D , 2006 .

[21]  Joseph F Contrera,et al.  Genetic toxicity assessment: employing the best science for human safety evaluation. Part I: Early screening for potential human mutagens. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  C. Selassie,et al.  History of Quantitative Structure–Activity Relationships , 2010 .

[23]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[24]  Raymond R Tice,et al.  Genetic toxicology in the 21st century: Reflections and future directions , 2011, Environmental and molecular mutagenesis.

[25]  Naomi L Kruhlak,et al.  Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities. , 2009, Regulatory toxicology and pharmacology : RTP.

[26]  Xiang-Qun Xie,et al.  Recent Advances in Fragment-Based QSAR and Multi-Dimensional QSAR Methods , 2010, International journal of molecular sciences.

[27]  N. Kruhlak,et al.  An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods. , 2006, Regulatory toxicology and pharmacology : RTP.

[28]  J. Contrera,et al.  Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices. , 2003, Regulatory toxicology and pharmacology : RTP.

[29]  Edwin J Matthews,et al.  In silico approaches to explore toxicity end points: issues and concerns for estimating human health effects , 2007, Expert opinion on drug metabolism & toxicology.

[30]  R. Tennant,et al.  Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. , 1991, Mutation research.

[31]  Marvin Johnson,et al.  Concepts and applications of molecular similarity , 1990 .

[32]  Naomi L Kruhlak,et al.  Combined Use of MC4PC, MDL-QSAR, BioEpisteme, Leadscope PDM, and Derek for Windows Software to Achieve High-Performance, High-Confidence, Mode of Action–Based Predictions of Chemical Carcinogenesis in Rodents , 2008, Toxicology mechanisms and methods.

[33]  Naomi L Kruhlak,et al.  A comprehensive model for reproductive and developmental toxicity hazard identification: I. Development of a weight of evidence QSAR database. , 2007, Regulatory toxicology and pharmacology : RTP.

[34]  Naomi L. Kruhlak,et al.  In Silico Screening of Chemicals for Genetic Toxicity Using MDL-QSAR, Nonparametric Discriminant Analysis, E-State, Connectivity, and Molecular Property Descriptors , 2008, Toxicology mechanisms and methods.